Wordt geladen...
Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial
AIMS: To investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or type 1 diabetes (T1D) treated with insulin who have elevated LDL cholesterol levels despite maximally tolerated statin therapy. METHODS: Participants at high cardiovascular risk with T2D (n = 441) or T1D...
Bewaard in:
| Gepubliceerd in: | Diabetes Obes Metab |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Blackwell Publishing Ltd
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5698740/ https://ncbi.nlm.nih.gov/pubmed/28905478 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13114 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|